.AstraZeneca execs claim they are "not anxious" that the failure of tozorakimab in a period 2 persis...
.Welcome to this week's Chutes & Ladders, our summary of considerable leadership hirings, firings...
.After showing plannings to hit the U.S. public markets less than a month earlier, Zenas Biopharma a...
.Psyence Biomedical is paying out $500,000 in shares to get fellow psilocybin-based biotech Clairvoy...
.Five months after signing off on Utility Therapeutics' Pivya as the very first brand new therapy fo...
.Eli Lilly has vaulted into an AI-enabled drug finding deal, partnering with RNA specialist Heredita...
.Lykos chief executive officer as well as owner Amy Emerson is walking out, along with chief running...
.Novartis levels a brand new outpost in its partnership along with Voyager Therapies, paying $15 mil...
.On the heels of an FDA turndown for its primary rival Novo Nordisk, Eli Lilly is actually pulling a...
.Just a few months after dosing the very first patient in a phase 2 test for recently diagnosed glio...